Does alpha-ketoglutarate slow aging or reverse biological age?

AKG is not a foreign compound — it is something your body produces constantly as part of normal metabolism. By middle age, circulating levels have dropped to a fraction of what they were in youth. Supplementing is essentially a way to restore a physiologically normal molecule, which helps explain its strong safety profile.

Energy Metabolism and the Krebs Cycle

AKG is a key intermediate in the tricarboxylic acid (TCA) cycle, where it is converted into succinyl-CoA with the release of carbon dioxide and NADH. This step is central to how cells convert nutrients into ATP. When AKG is abundant, the cycle runs more efficiently, supporting energy-intensive processes like cell repair and immune function³.

Epigenetic Regulation

One of AKG's more striking roles is as a co-substrate for a family of enzymes called TET dioxygenases and Jumonji-domain histone demethylases. These enzymes are responsible for removing methyl groups from DNA and histones — a core mechanism of epigenetic regulation. As AKG declines with age, this demethylation activity slows, contributing to the accumulation of aberrant DNA methylation patterns that are a hallmark of biological aging. Supplementing AKG restores the substrate availability these enzymes need to keep the epigenome in a younger configuration^3,2.

mTOR Inhibition

AKG inhibits ATP synthase and, as a downstream consequence, suppresses mTOR — the growth-sensing pathway that, when chronically overactivated in aging, promotes cell senescence and suppresses autophagy. Inhibiting mTOR is one of the most well-validated approaches to extending lifespan in animal models, shared with drugs like rapamycin. AKG appears to achieve this through a metabolic rather than pharmacological mechanism^1,3.

Anti-Inflammatory Effects

Chronic low-grade inflammation ("inflammaging") is central to aging-related disease. AKG, particularly as Ca-AKG, has been shown to induce IL-10 — an anti-inflammatory cytokine — while reducing the systemic inflammatory burden marked by TNF-α, IL-6, and other pro-inflammatory signals. In the mouse studies, frailty scores improved significantly alongside these inflammatory changes¹.

Bone and Connective Tissue Support

AKG regulates histone methylation in bone marrow mesenchymal stem cells, promoting their osteogenic (bone-forming) potential. In aged mice, AKG administration increased bone mass and attenuated age-related bone loss, suggesting a role in maintaining skeletal integrity⁵. AKG is also a precursor to proline and hydroxyproline, both of which are essential building blocks for collagen.

Practical Dosage

• Form: Calcium alpha-ketoglutarate (Ca-AKG) is the most studied form; the calcium salt makes it shelf-stable and well-absorbed
• Dose: Most research uses 1 gram per day; some protocols use 1–2 g/day
• Safety: Ca-AKG is Generally Recognized as Safe (GRAS) by the FDA; no significant adverse effects have been reported in clinical research
• Timing: Can be taken with or without food; no established timing advantage
• Not a replacement for: exercise, sleep, whole foods, or other established longevity practices — best understood as a supportive intervention within a broader lifestyle

See our NAD+ page and spermidine page for other metabolite-based longevity approaches.

Animal Research: Lifespan and Healthspan in Mice

The foundational study by Asadi Shahmirzadi et al. (PMID 32877690), published in Cell Metabolism in 2020, is the most important preclinical work on AKG. The researchers supplemented middle-aged C57BL/6 mice with Ca-AKG starting at approximately 18 months of age (equivalent to late middle age in humans). Key findings:

• Female mice showed a median lifespan extension of approximately 12% and a maximum lifespan extension of about 10%
• Both male and female mice showed significant improvements in healthspan metrics, including reduced frailty scores on validated frailty indexes
• Systemic inflammatory cytokines (TNF-α, IL-6, CXCL1) were significantly reduced
• Collagen and hair coat quality — physical markers of aging — were measurably improved
• Importantly, the supplement compressed morbidity: mice lived healthier for longer before dying, rather than extending the period of illness

The mechanism was attributed to ATP synthase inhibition leading to mTOR suppression, combined with reduced inflammation via IL-10 induction. This study used Ca-AKG in the diet at a dose equivalent to roughly 1–2 g/day in humans.

Limitations: mouse physiology differs from human physiology; many longevity interventions that work in mice fail to translate. The result in females was stronger than in males, which may reflect differences in metabolic baseline.

Human Review: State of the Evidence

Gyanwali et al. (PMID 34952764), publishing in Trends in Endocrinology and Metabolism in 2022, reviewed all available evidence on AKG supplementation in humans. Their synthesis found:

• Strong mechanistic data in cell and animal models
• Early observational and pilot data in humans, primarily the Rejuvant retrospective analysis, which reported an average 8-year reduction in biological age (measured by TruAge DNA methylation clock) after an average of 7 months of supplementation in 42 individuals — though this was uncontrolled and retrospective
• The authors identified the need for blinded, randomized controlled trials in humans as the critical next step
• They flagged AKG's safety profile as strong relative to more aggressive longevity interventions like rapamycin

The 2022 review emphasized that AKG's epigenetic mechanism — specifically, its role as a co-factor for TET enzymes — is particularly compelling given the current understanding of DNA methylation as a driver of biological aging.

Comprehensive Review: Mechanisms and Multi-Species Evidence

Naeini et al. (PMID 36934991), published in Experimental Gerontology in 2023, reviewed evidence across C. elegans, Drosophila, mice, and humans. Key findings:

• In C. elegans, AKG supplementation extended lifespan by 50% in some experiments, acting through TOR signaling suppression
• In Drosophila, lifespan extension was associated with improved reproductive function and stress resistance
• In mice, both the Cell Metabolism results and additional studies confirmed healthspan benefits
• In humans, the mechanisms converge on the same pathways seen in animal models
• The authors concluded that AKG is one of the most biologically coherent anti-aging interventions, with the advantage that it is endogenous to human metabolism

The ABLE Trial Protocol

Sandalova et al., in GeroScience in 2023, described the protocol for the ABLE (Alpha-ketoglutarate supplementation and BiologicaL agE) trial, a double-blind, placebo-controlled randomized trial of calcium alpha-ketoglutarate (Ca-AKG) in humans⁴. Details:

• 120 participants, ages 40–60, biologically older than their chronological age based on DNA methylation age
• Intervention: 1 gram sustained-release Ca-AKG vs. placebo daily for 6 months, followed by 3 months of follow-up
• Primary outcome: change in DNA methylation age from baseline to end of intervention
• Secondary outcomes: inflammatory and metabolic blood markers, handgrip strength, leg extension strength, arterial stiffness, skin autofluorescence (a marker of advanced glycation end-products), and VO2 max
• The authors note that including biologically older participants (elevated epigenetic age) is unique to this study

The protocol paper describes the design only and reports no results. Results from ABLE will be critical for determining whether the animal and observational human data translate to a real-world benefit in a controlled setting.

Bone Health: Epigenetic Mechanism in Aged Mice

Wang et al. (2020), published in Nature Communications, showed that AKG ameliorates age-related osteoporosis by regulating histone methylation⁵. In aged mice, administration of AKG increased bone mass and attenuated age-related bone loss. In bone marrow mesenchymal stem cells derived from aged mice, AKG ameliorated senescence-associated phenotypes and promoted proliferation, colony formation, migration and osteogenic (bone-forming) potential. Mechanistically, AKG decreased the accumulation of two histone methylation marks, H3K9me3 and H3K27me3, and subsequently upregulated BMP signaling and Nanog expression⁵. This links AKG's epigenetic role to a specific tissue-level aging outcome — age-related bone loss — in mice.

Overall Evidence Assessment

AKG has some of the strongest mechanistic rationale of any emerging longevity supplement. The Krebs cycle role, the epigenetic co-factor function, the mTOR-inhibiting properties, and the anti-inflammatory effects are all well-characterized in cell biology. Animal studies consistently show lifespan and healthspan benefits. Human evidence remains limited to retrospective and observational data, but the ABLE trial will provide the first rigorous human RCT data. Safety is excellent. This is a serious research area, not a fringe supplement claim — but anyone following it should wait for the randomized trial results before drawing strong conclusions about efficacy in humans.